Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 13Completed 9Terminated 5Unknown 4Active not recruiting 4Withdrawn 3Not yet recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Gastrointestinal 3Thoracic 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Mesothelioma, Malignant 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

Cisplatin 7Pemetrexed 6atezolizumab 5Carboplatin 4tislelizumab 3Paclitaxel 3Leucovorin 3Filgrastim 3Etoposide 3vistusertib 2pembrolizumab 2Vincristine 2Topotecan 2Temozolomide 2Tegafur 2Sorafenib 2Irinotecan 2Immunoenzyme Techniques 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2zirconium-89-trastuzumab 1vandetanib 1toripalimab 1temsirolimus 1tanespimycin 1talazoparib 1soblidotin 1selinexor 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × tislelizumab × Other solid neoplasm × Clear all
NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

BeiGene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumors

NCT05582031 2023-06-07

REFIT-MSS

Translational Research in Oncology

Phase 2 Withdrawn
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡